Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 337 - 344 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC2193 | AG-490 |
|
Selective inhibitor of EGF receptor tyrosine kinase (IC<sub>50</sub> values are 2 and 13.5 <span class='symbol'>μ</span>M for EGFR and ErbB2 respectively). Inhibitor of JAK2, JAK3/STAT, JAK3/AP-1 and JAK3/MAPK pathways and potently inhibits cytokine-independent cell growth <em>in vitro</em> and tumor cell invasion <em>in vivo</em>.
|
|
| BCC2202 | WHI-P154 |
|
JAK3 inhibitor (IC<sub>50</sub> = 1.8 <span class='symbol'>μ</span>M) that displays no activity at JAK1 or JAK2. Inhibits STAT1 activation, iNOS expression and NO production in macrophages <em>in vitro</em>. Also inhibits other common kinases including EGFR (IC<sub>50</sub> = 4 nM), Src, Abl, VEGFR, MAPK and PI 3-K and induces apoptosis in human glioblastoma cell lines (IC<sub>50</sub> = 158 <span class='symbol'>μ</span>M). Induces differentiation of neural progenitor cells.
|
|
| BCC2208 | Iniparib (BSI-201) |
|
PARP1 inhibitor. Inhibits growth of certain breast cancer cell lines in vitro. Non-selectively modifies cysteine-containing proteins in tumor cells. Inhibits ionizing radiation-induced DNA single-stranded breaks in lymphoid cell lines in vivo.
|
|
| BCC2210 | PJ34 hydrochloride |
|
Potent inhibitor of poly(ADP-ribose) polymerase (PARP) (EC<sub>50</sub> = 20 nM). ~1000-fold more potent than 3-Aminobenzamide. Protects primary neuronal cells from oxygen-glucose deprivation <em>in vitro</em> and reduces infarct size following focal cerebral ischemia <em>in vivo</em>. Displays protective effects against cisplatin-induced kidney injury. Also displays activity at Pim-1 and Pim-2 kinases at higher concentrations (IC<sub>50</sub> values are 3.7 and 16 <span class='symbol'>μ</span>M respectively).
|
|
| BCC2212 | INO-1001 |
|
An inhibitor of poly(ADP-ribose) polymerase, which protects cells from UV-B-induced apoptosis via influence on the cytoskeleton.
|
|
| BCC2213 | UPF 1069 |
|
Selective poly(ADP-ribose) polymerase (PARP) 2 inhibitor (IC<sub>50</sub> values are 0.3 and 8.0 <span class='symbol'>μ</span>M for PARP-2 and PARP-1 respectively).
|
|
| BCC2217 | Entacapone |
|
Potent catechol <em>O</em>-methyltransferase (COMT) inhibitor (IC<sub>50</sub> values are 14.3, 20.1 and 73.3 nM for rat liver soluble COMT, total COMT and membrane-bound COMT respectively). Increases bioavailability of levodopa when given as an adjunct therapy for Parkinson's disease. Inhibits <span class='symbol'>α</span>-synuclein aggregation in an <em>in vitro</em> assay; blocks <span class='symbol'>α</span>-synuclein-induced cell death in PC-12 cells.
|
|
| BCC2218 | EPZ004777 |
|
Highly potent DOT1L inhibitor (IC<sub>50</sub> = 0.4 nM). Exhibits >1000-fold selectivity for DOT1L over a panel of other methyltransferases. Selectively inhibits proliferation and induces apoptosis of <em>MLL</em>-rearranged cells <em>in vitro</em>. Prolongs survival in a MLL xenograft mouse model.
|
|